Phylogica partnership with Pfizer hits first milestone
Tuesday, 13 December, 2011
A collaboration between peptide-based drug discovery company Phylogica (ASX:PYC) and Pfizer has yielded its first milestone payment for the Australian biotech.
The collaboration, which began in December 2010, saw Phylogica employ its Phylomer peptide libraries and screening technology to identify novel peptide drug candidates.
Phylogica reports that it has identified several peptides that will be further evaluated as potential vaccines against an undisclosed target.
“We are very pleased to report the successful completion of the initial phase of our collaboration with Pfizer,” said Phylogica CEO Dr Paul Watt.
“We have identified multiple novel phylomers that meet the criteria required for further evaluation by Pfizer. This provides additional support for the potential value of our phylomer libraries as a source of novel peptide drug candidates.”
The milestone payment to Phylogica was for an undisclosed amount.
Phylogica (ASX:PYC) is currently trading at 5.7c.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...